Effect of oteracil in combination with gimeracil on longterm survival and postoperative complications in elderly patients undergoing radical surgery for biliary tract cancer

Abstract

Purpose: To investigate the effect of oteracil (Oxo) in combination with gimeracil (CDHP) on long-term survival and postoperative complications in elderly patients undergoing radical surgery for biliary tract cancer (BTC).Methods: Clinical data for 70 patients who underwent radical surgery for BTC in the Oncology Department of the Changle People’s Hospital, Weifang, China from April 2017 to April 2018 were collected. The patients were equally assigned to group A and group B, based on odd or even hospitalization number. After surgery, patients in group A received the combination of Oxo and CDHP, while group B patients received gemcitabine only. Long-term survival and incidence of adverse reactions were compared.Results: Compared with group B, group A had higher total treatment effectiveness (p < 0.05), lower clinical indices (p < 0.05), lower BPI score (p < 0.001) and higher 3-year overall survival (p < 0.05).Conclusion: Combined use of oteracil and gimeracil significantly prolongs the survival time and reduce cancer pain in BTC patients, with minimal toxic and side effects. However, further clinical trials are required prior to application in clinical practice.